Dowdy Jackson’s Post

This is a very good manuscript about things to consider when developing various antibody therapies.

I am reposting a new link to my article about the ADC landscape and the recent flurry of ADC deals. Which deals make sense and which deals seem questionable ? https://lnkd.in/e4JgESSw

I have posted my slides from the webinar on ADC linker design. If you have any questions, feel free to send me a message. https://lnkd.in/eDTgpRH6

This sounds like a great opportunity from JLabs for those interested in creating the next generation ADCs. https://lnkd.in/ePj38xnw

Now that the dust has settled from the last round of ADC deals, let's take a look at the overview of the ADC deals. Which deals make sense and which deals raise questions? https://lnkd.in/e4JgESSw

On this day we celebrate Juneteenth. We have made great achievements through hard work, sacrifice and preseverance but we still have much more work to do. Congratulations to Anthony Johnson for being included on this prestigious list. https://lnkd.in/eRNxtJvp

BioNTech/MediLink's HER3 ADC has been placed on partial hold by the FDA due to concerns that BNT326/YL202 “may, at higher doses, expose human subjects to unreasonable and significant risk of illness or injuries.” Apparently they had patient deaths at 4mg/kg and 5.5mg/kg. They are using a proprietary topoisomerase I inhibitor and a tripeptide linker with a DAR of 8. In their ASCO publication they mentioned they would focus on developing the ADC at doses below 4mg/kg. https://lnkd.in/es4DPMjS

In case you missed our webinar on ADC linker design and how it impacts ADC performance, you can see it here.

Abbvie is reaping the benefits of their purchase of Immunogen. It will be interesting to see how they manage this ADC and develop their ADC pipeline.

Looking forward to seeing more data from Immunocore. Dr. Bahija Jallal, Ph.D. has done a great job leading this company. I remember her guidance and leadership at MedImmune. Check out the interview at ASCO.